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referral was 0.32 µg/L (range: 0.016 – 4.65 µg/L). MRI did not 
show any suspected macroscopic disease in 137 patients 
(74.9%). In 46 (25.1%) patients, MRI did indicate a local (n = 
19) and/or pelvic (n = 29) recurrence, suspected bone lesions 
were observed in two patients. The mean rPSA was 
significantly higher in patients with a suspected recurrence 
on MRI than in patients with a negative MRI (0.42 µg/L vs. 
1.35 µg/L, p = 0.00002) on a Student t-test. The mean follow-
up was 33.1 months (range: 5 – 69 months). Biochemical 
disease-free survival was significantly worse in patients with 
suspected macroscopic disease on MRI (HR 2.867, p < 0.0001) 
(see Figure), this result remained independently significant 
after Multivariate Cox regression analysis (HR 2.496, 95% CI 
1.376 – 4.528, p = 0.0003). Furthermore, androgen 
deprivation therapy-free survival was significantly worse in 
patients with a suspected recurrence on MRI (HR 4.02, p < 
0.0001), this result also remained independently significant 
after Multivariate Cox regression analysis (HR 3.4, 95% CI 
1.524 - 7.591, p = 0.003). 
In a second analysis, the location of the suspected lesions will 
be correlated to the irradiated PTVs as well as the EORTC 
guidelines. Also, the volume of the recurrence will be 
correlated to the rPSA levels.  
 
 
 
 
 
Conclusions: MRI, especially with diffusion-weighted 
sequences, detects loco-regional disease in a substantial 
subset of patients with a biochemical recurrence after 
prostatectomy, particularly when rPSA is above 0.5 µg/L. 
Lack of MRI-based dose escalation on these macroscopic 
recurrences could explain some of the biochemical 
progression observed after salvage radiotherapy. 
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To aid in radiotherapy planning for the future, a series of 
recent studies on health economic aspects of radiation 
oncology in Europe have been published by HERO - the ESTRO 
Health Economics in Radiation Oncology project. HERO has 
the overall aim to develop a knowledge base of the provision 
of radiotherapy in Europe and build a model for health 
economic evaluation of radiation treatments at the European 
level. The first step has been to provide a validated picture 
of the European radiotherapy landscape in terms of 
availability of equipment, personnel and guidelines, and to 
estimate the need for radiotherapy in European countries. 
The access to radiotherapy was studied using an 84-item 
questionnaire, distributed to the 40 countries of the 
European Cancer Observatory. The results showed a huge 
variation in the availability and sophistication of treatment 
equipment and staffing levels across Europe. The median 
number of MV units per million inhabitants was 5.3, with a 
seven-fold variation across the European countries. Staffing 
figures showed a twenty-fold variation, even after grouping 
personnel with comparable duties in the radiotherapy 
process. Guidelines for equipment and human resources were 
declared for most countries, but without explicitly providing 
metrics for developing capital and human resource 
inventories in many cases. Both staffing and access to 
modern radiotherapy (IMRT and IGRT) was correlated to 
economic status (GNI/n), but large differences were observed 
also between countries with higher GNI/n, indicating that 
health policy has a significant impact on the provision of 
services. 
The evidence-based need for radiotherapy, in terms of 
number of cancer patients requiring radiotherapy, can be 
estimated from merging epidemiological data with evidence-
based clinical decision trees. The CCORE studies based on 
Australian data have indicated that about 50% of all cancer 
patients will at some point in their disease need 
radiotherapy. In a recent European HERO study these 
estimates have been refined with details about tumour site 
and stage relevant for each of the European countries. The 
results indicate that variations in tumour site more than 
stage influence this optimal proportion; on average 51% of 
European cancer patients are candidates for radiotherapy. 
A major question which is currently being explored by HERO 
is the discrepancy observed between the actual utilization 
and the optimal utilization of radiotherapy in European 
countries. A comparison to the actually delivered 
radiotherapy courses published in the HERO studies revealed 
that the optimal radiotherapy utilization benchmark is not 
met in the vast majority of countries, not even the most 
affluent and well-served countries. Reasons for this striking 
discrepancy may in some instances be directly related to lack 
of access to radiotherapy resources, but other factors 
including local and national treatment traditions, referral 
patterns, patient preferences, geography, co-morbidity, 
reimbursement rules etc. may also play significant roles. To 
uncover these mechanisms is important for radiation 
oncology and warrants further studies. 
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